Urogen Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
Urogen Pharma (NASDAQ:URGN) executives used the company's fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product Jelmyto, and a strengthened balance sheet following a refinancing with Pharmakon Advisors. Management also outlined upcoming clinical and regulatory milestones across its next-generation pipeline, including plans for an NDA submission for UGN-103 in the second half of 2026. Zusduri launch: J-code seen as key catalyst for uptake Chief Executive Officer Liz Barrett said the company's “top priority” is the commercial launch of Zusduri in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). Barrett pointed to an “encouraged” early 2026 trajectory following the permanent J-code becoming effective on Jan. 1, which she described as removing a key barrier to adoption by enabling more predictable patient access. ? The Head Fake: Buying the Chinese Stocks Post-Rulin
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- Urogen Pharma (URGN) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
- UroGen (URGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors [Yahoo! Finance]Yahoo! Finance
URGN
Earnings
- 3/2/26 - Beat
URGN
Analyst Actions
- 3/2/26 - Oppenheimer Holdings, Inc.
URGN
Sec Filings
- 3/2/26 - Form 10-K
- 3/2/26 - Form 8-K
- 3/2/26 - Form 8-K
- URGN's page on the SEC website